Reprint

Hypoxia-Inducible Factors: Regulation and Therapeutic Potential

Edited by
January 2022
200 pages
  • ISBN978-3-0365-2912-7 (Hardback)
  • ISBN978-3-0365-2913-4 (PDF)

This book is a reprint of the Special Issue Hypoxia-Inducible Factors: Regulation and Therapeutic Potential that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Oxygen is an essential molecule in the production of adenosine triphosphate (ATP) in cells, and a lack of energy due to O2 deficiency makes the maintenance of biological functions and human life improbable. Since oxygen functions as the final electron acceptor in the series of ATP synthesis reactions in conjunction with oxidative phosphorylation in mitochondria, its deficiency causes the oxidation of a series of coenzymes, such as nicotinamide and flavin adenine dinucleotide, and the reduction in oxygen molecules to water molecules (H2O). Mammals do not have a mechanism for biosynthesizing oxygen in their bodies. In higher organisms such as vertebrates, which possess many organs, oxygen in the body is always “scarce,”; therefore, the dominant view is that organisms have evolved mechanisms to respond to the lack of this essential molecule (hypoxia), and actively use it to maintain bodily integrity. Anatomically complex, higher multicellular organisms are equipped with specialized mechanisms to enable all cells to obtain sufficient oxygen. The proper development and preservation of these systems requires the harmonious expression of thousands of genes. The transcription factor responsible for this gene expression is hypoxia-inducible factor 1 (HIF-1).

In this Special Issue, we invited research and review papers on various areas of oxygen biology research that focused on the fundamental understanding of HIF signaling pathways and related gene expression profiling, as well as pharmacogenomic biomarkers, molecular targets driving the regulation of human physiology and pathophysiology, and validation in animal models.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
hypoxia; transcriptome; RNA-seq; ChIP-seq; public database; meta-analysis; peripheral blood cells; blood-derived therapy; hypoxia; angiogenesis; platelet rich plasma (PRP); hypoxia preconditioned plasma; hypoxia preconditioned serum; hypoxia; transcription factor; hypoxia-inducible factor 1; HIF-1; hypoxia sensing; acetylsalicylic acid; angiogenesis; blood-derived therapy; COX-1; clopidogrel; drug anticoagulation; hypoxia; hypoxia preconditioned plasma; hypoxia preconditioned serum; NOACs; peripheral blood cells; oral anticoagulation; VEGF; adipose-derived stem cells; adipose-derived cell supension; peripheral blood cells; blood-derived therapy; hypoxia; angiogenesis; hypoxia preconditioned plasma; hypoxia preconditioned serum; lymphangiogenesis; lymphatic regeneration; hypoxia; macrophage; matrix metalloproteinase; atherosclerotic plaque rupture; oxidative stress; xanthine oxidase; hypoxia; HIF; T cells; B cells; monocytes; macrophages; neutrophils; ILC; oxygen; hypoxia; transcription factor; hypoxia-inducible factor 1; HIF-1; hypoxia sensing; HIF-PH inhibitor; hypoxia; RNA-seq; ChIP-seq; gene2pubmed; bibliome; meta-analysis; signature genes; GPR146; enrichment analysis; n/a